Health

Nature Medicine, Published online: 04 June 2025; doi:10.1038/s41591-025-03734-3

A single-arm phase 2 trial in patients with mostly PD-L1-negative advanced triple-negative breast cancer shows that treatment with the anti-PD-L1 agent atezolizumab, paclitaxel and the anti-VEGF agent bevacizumab prolongs progression-free survival.

Nature Medicine, Published online: 03 June 2025; doi:10.1038/s41591-025-03685-9

A large international panel of experts reach consensus on a new standard for reporting settings in psychedelic trials, identifying 30 key non-pharmacological factors to strengthen the rigor of psychedelic research.

Nature Medicine, Published online: 03 June 2025; doi:10.1038/s41591-025-03739-y

A single dose of the anti-sporozoite monoclonal antibody CIS43LS can achieve durable, sterile protection against Plasmodium falciparum infection.

Nature Medicine, Published online: 03 June 2025; doi:10.1038/s41591-025-03743-2

Preliminary results from a phase 2a trial involving 71 patients suggest that a new agent, discovered and designed with artificial intelligence assistance, is safe and effective for the treatment of idiopathic pulmonary fibrosis.

Nature Medicine, Published online: 03 June 2025; doi:10.1038/s41591-025-03693-9

An analysis of 18 metagenomic datasets of individuals with colorectal cancer, adenomas and healthy controls yields improved cancer prediction accuracy based solely on gut metagenomics, as well as the identification of new species associated with the development of cancer.

The idea that a base tan is a natural sunscreen that protects you from sunburn and skin cancer is incorrect. According to Dallas, Texas–based dermatologist Dr. Elizabeth Bahar Houshmand, “skin damage starts with your very first tan,” and every subsequent tan only compounds the damage and risk. Instead of hitting the beach or tanning bed early in the season in hopes of protecting yourself later on, follow dermatologists’ advice and use sunscreen lotion and wear hats and clothing that provide ultraviolet protection.

Nature Medicine, Published online: 02 June 2025; doi:10.1038/s41591-025-03728-1

Bridging the vaccine divide

Nature Medicine, Published online: 01 June 2025; doi:10.1038/s41591-025-03745-0

As presented at the 2025 ASCO Annual Meeting, intracerebroventricular infusion of bivalent CAR T cells targeting EGFR and IL-13Rα2 in patients with multifocal, recurrent glioblastoma was feasible and well tolerated, with the maximum tolerated dose identified, one patient with a partial response and one patient with durable stable disease.

Nature Medicine, Published online: 31 May 2025; doi:10.1038/s41591-025-03738-z

As presented at the 2025 AUA Annual Meeting: in a randomized controlled phase 3 trial evaluating subcutaneous administration of sasanlimab, an anti-PD-1 inhibitor, with Bacillus Calmette–Guérin induction and maintenance treatment, combination treatment significantly improved event-free survival versus standard-of-care therapy.

Nature Medicine, Published online: 31 May 2025; doi:10.1038/s41591-025-03746-z

As presented at the 2025 ASCO Annual Meeting: in a randomized platform phase II trial, high rates of pathologic complete response were seen for neoadjuvant durvalumab plus chemotherapy when combined with new agents, most notably a TROP2-targeting antibody–drug conjugate, in patients with resectable non-small-cell lung cancer.